Citigroup
CRL icon

Citigroup’s Charles River Laboratories CRL Stock Holding History

Citigroup’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,000
Closed -$2.9M – 7624
2019
Q4 		$2.9M Buy
+19,000
New +$2.63M ﹤0.01% 2580

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Cooke & Bieler
Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup's CRL Position: Q3 2026 in Review

Citigroup reduced its Charles River Laboratories (CRL) stake by 59% in Q3 2026, selling an estimated $49M and leaving 130,312 shares worth $38.4M. The position accounts for 0.01% of the portfolio, ranked #878.

Citigroup first reported a position in CRL in Q2 2013 and has held it in 54 quarters since. The position peaked at $71.7M in Q2 2026. 353 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Citigroup held 130,312 shares of Charles River Laboratories worth $38.4M as of Q3 2026.
  • Citigroup sold 185,905 Charles River Laboratories shares in Q3 2026, an estimated $49M.
  • Charles River Laboratories made up 0.01% of Citigroup's portfolio in Q3 2026, its #878 holding.
  • Citigroup first reported a position in Charles River Laboratories in Q2 2013 and has held it in 54 quarters since.
  • Citigroup's Charles River Laboratories position peaked at $71.7M in Q2 2026.
  • 353 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.